{"id":20949,"date":"2025-01-08T16:03:15","date_gmt":"2025-01-08T08:03:15","guid":{"rendered":"https:\/\/flcube.com\/?p=20949"},"modified":"2025-01-08T16:03:16","modified_gmt":"2025-01-08T08:03:16","slug":"variant-bio-partners-with-novo-nordisk-to-discover-novel-targets-for-metabolic-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20949","title":{"rendered":"Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases"},"content":{"rendered":"\n

US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE: NVO<\/a>) to jointly discover novel targets for the treatment of metabolic diseases. The collaboration is designed to identify and validate multiple innovative targets with strong human genetic evidence, paving the way for human-centric drug discovery programs.<\/p>\n\n\n\n

Role of Variant Bio’s Platform<\/strong>
Variant Bio will utilize its innovative VB-Inference analysis platform to identify novel targets with robust genetic evidence and clear therapeutic hypotheses. This platform has already enabled several new R&D programs within Variant Bio’s internal pipeline. It maps the molecular mechanisms of disease by integrating whole genomes with deep phenotyping and rich multi-omic data, leveraging statistical genetics and machine learning.<\/p>\n\n\n\n

Significance of the Partnership<\/strong>
This partnership underscores the commitment of both Variant Bio and Novo Nordisk to advancing the understanding and treatment of metabolic diseases. By combining Variant Bio’s advanced genomics capabilities with Novo Nordisk’s expertise in drug development, the collaboration aims to accelerate the discovery of innovative therapies that could significantly improve patient outcomes.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE:…<\/p>\n","protected":false},"author":1,"featured_media":20951,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[148,860,3083],"class_list":["post-20949","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-novo-nordisk","tag-nyse-nvo","tag-variant-bio"],"yoast_head":"\nVariant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE: NVO) to jointly discover novel targets for the treatment of metabolic diseases. The collaboration is designed to identify and validate multiple innovative targets with strong human genetic evidence, paving the way for human-centric drug discovery programs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20949\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases\" \/>\n<meta property=\"og:description\" content=\"US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE: NVO) to jointly discover novel targets for the treatment of metabolic diseases. The collaboration is designed to identify and validate multiple innovative targets with strong human genetic evidence, paving the way for human-centric drug discovery programs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20949\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T08:03:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-08T08:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0809.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20949#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20949\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases\",\"datePublished\":\"2025-01-08T08:03:15+00:00\",\"dateModified\":\"2025-01-08T08:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20949\"},\"wordCount\":193,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20949#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0809.png\",\"keywords\":[\"Novo Nordisk\",\"NYSE: NVO\",\"Variant Bio\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20949#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20949\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20949\",\"name\":\"Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20949#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20949#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0809.png\",\"datePublished\":\"2025-01-08T08:03:15+00:00\",\"dateModified\":\"2025-01-08T08:03:16+00:00\",\"description\":\"US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE: NVO) to jointly discover novel targets for the treatment of metabolic diseases. The collaboration is designed to identify and validate multiple innovative targets with strong human genetic evidence, paving the way for human-centric drug discovery programs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20949#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20949\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20949#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0809.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0809.png\",\"width\":1080,\"height\":720,\"caption\":\"Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20949#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases - Insight, China's Pharmaceutical Industry","description":"US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE: NVO) to jointly discover novel targets for the treatment of metabolic diseases. The collaboration is designed to identify and validate multiple innovative targets with strong human genetic evidence, paving the way for human-centric drug discovery programs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20949","og_locale":"en_US","og_type":"article","og_title":"Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases","og_description":"US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE: NVO) to jointly discover novel targets for the treatment of metabolic diseases. The collaboration is designed to identify and validate multiple innovative targets with strong human genetic evidence, paving the way for human-centric drug discovery programs.","og_url":"https:\/\/flcube.com\/?p=20949","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-08T08:03:15+00:00","article_modified_time":"2025-01-08T08:03:16+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0809.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20949#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20949"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases","datePublished":"2025-01-08T08:03:15+00:00","dateModified":"2025-01-08T08:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20949"},"wordCount":193,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=20949#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0809.png","keywords":["Novo Nordisk","NYSE: NVO","Variant Bio"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20949#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20949","url":"https:\/\/flcube.com\/?p=20949","name":"Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=20949#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=20949#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0809.png","datePublished":"2025-01-08T08:03:15+00:00","dateModified":"2025-01-08T08:03:16+00:00","description":"US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE: NVO) to jointly discover novel targets for the treatment of metabolic diseases. The collaboration is designed to identify and validate multiple innovative targets with strong human genetic evidence, paving the way for human-centric drug discovery programs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20949#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20949"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=20949#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0809.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0809.png","width":1080,"height":720,"caption":"Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20949#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0809.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20949"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20949\/revisions"}],"predecessor-version":[{"id":20952,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20949\/revisions\/20952"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/20951"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}